A randomized control study for evaluating the efficacy of individualized homoeopathic medicine as an adjuvant therapy in mild to moderate cases of COVID-19

Abstract

Understanding the efficacy of indicated homoeopathic medicine as an adjuvant to standard treatment in improving the subjective and objective parameters in patients with mild to moderate confirmed cases of COVID-19. Study design: A prospective randomized control trial conducted at Deenanath Mangeshkar Hospital, Erandwane, Pune, wherein Group A received standard treatment along with indicated homoeopathic medicine (experimental group) and Group B received the standard treatment and placebo (control group). Sample size: Fifty confirmed COVID positive, randomly selected patients in Groups A and B. The indicated homoeopathic medicine as an adjuvant reduced subjective distress in a statistically significant proportion. It also reduced oxygen requirement, shortened hospital stay, promoted early recovery, and reduced worsening of the patients and shifting into the intensive care unit (ICU). By day 4 of treatment, subjective symptoms in 56% of patients in the experimental group were completely resolved, compared to 15% in the control group. The oxygen requirement on day 4 reduced by 46.2% in the experimental group, remaining unchanged in the control group. None of the patients in the experimental group needed shifting to the ICU compared to 16.7% in the control group. The average hospital stay was 6 days in the experimental group, compared to 9 days in the control group. Homoeopathic medicines played a significant role in helping to relieve the subjective and objective parameters of COVID-19.